FDA Picks Eli Lilly, Regeneron for Fast-Track Plant Review Pilot
The FDA selected seven companies, including Eli Lilly and Regeneron, for its new PreCheck Pilot Program to speed manufacturing facility reviews.
The FDA just picked its first wave of companies for a program designed to cut through the red tape slowing down new drug manufacturing approvals — and two big names are on the list. Eli Lilly and Regeneron are among seven firms tapped for the agency's PreCheck Pilot Program, according to CNBC reporting. This is the kind of regulatory move that could actually matter for drug supply chains and production timelines.
The PreCheck Pilot Program is built to accelerate how the FDA reviews new manufacturing facilities. If you trade pharma or biotech, you already know that facility approval delays are one of the most frustrating — and stock-moving — bottlenecks in the entire drug development pipeline. Getting a plant greenlit faster means faster commercialization, and that's a direct line to revenue.
Read more iPhone 18 Pro Secrets Leaked After Tata Electronics Ransomware Hit →
For Eli Lilly specifically, the timing is notable. The company has been under enormous pressure to scale up manufacturing capacity for its weight-loss and diabetes drugs, which have faced persistent supply constraints. A faster facility review process could help Lilly close the gap between demand and production capacity sooner than the market expects.
Regeneron brings a different profile to the program — a biotech known for complex biologics that require precision manufacturing environments. Being selected early signals that the FDA is serious about including both large pharma and specialized biotech players in this initiative, not just legacy manufacturers.
This pilot is worth watching. If PreCheck delivers on its promise, it sets a template for how the agency handles facility reviews going forward — and that has implications for the entire sector, not just these seven companies. Continue reading at US Top News and Analysis.
